Breast Cancer Update 2006 #4: unusual case reports & clinical trial comments
The latest BCU (volume 5, #4) has a number of unusual features in some of the audio interviews of clinical trial investigators at this web site:
http://www.breastcancerupdate.com/20...rs/default.asp In addition to the usual expert comments there are a number of patient interviews about their treatment. In the case of Dr Charles Fogel these interesting tracks (if you donot want to listen to the whole interview): (http://www.breastcancerupdate.com/bcu2006/4/vogel.asp) Track 2 Case discussion 1: A 61-year-old woman with metastatic breast cancer to the liver treated with high-dose estrogen therapy Track 14 Case discussion 5: A woman treated with trastuzumab for metastatic breast cancer since 1998 Track 21 Case discussion 6: Woman with prolonged response to trastuzumab Track 22Patient interview: Personal perspective on living with metastatic breast cancer Track 23Breast cancer as a chronic disease In the case of Dr Cathy Miller most of her interview is devoted to Bevacizumab(Avastin) which is a humanized monoclonal antibody, and was the first commercially available angiogenesis inhibitor (originally approved for colon cancer in 2004) & now tried for breast cancer. http://www.breastcancerupdate.com/bcu2006/4/miller.asp Two tracks (not on Avastin) of potential interest to triple negative patients & a third for low dose chemo cases: Track 10 Potential role of small molecule tyrosine kinase inhibitors (SMTKIs) in breast cancer Track 11Case discussion: Woman with ER/PR/HER2-negative metastatic disease treated with a SMTKI Track 27Pilot study of adjuvant bevacizumab monotherapy versus bevacizumab with metronomic chemotherapy The interview of Dr Jones is entirely devoted to chemo trials: http://www.breastcancerupdate.com/bcu2006/4/jones.asp |
All times are GMT -7. The time now is 01:18 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021